Vaxcyte Statistics

Total Valuation

Vaxcyte has a market cap or net worth of $8.08 billion. The enterprise value is $6.62 billion.

Market Cap	8.08B
Enterprise Value	6.62B

Important Dates

The last earnings date was Wednesday, May 8, 2024, after market close.

Earnings Date	May 8, 2024
Ex-Dividend Date	n/a

Share Statistics

Vaxcyte has 108.80 million shares outstanding. The number of shares has increased by 29.56% in one year.

Shares Outstanding	108.80M
Shares Change (YoY)	+29.56%
Shares Change (QoQ)	+8.94%
Owned by Insiders (%)	0.60%
Owned by Institutions (%)	112.11%
Float	99.31M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	4.07
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 17.42, with a Debt / Equity ratio of 0.01.

Current Ratio	17.42
Quick Ratio	n/a
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -28.80% and return on invested capital (ROIC) is -25.42%.

Return on Equity (ROE)	-28.80%
Return on Assets (ROA)	-26.90%
Return on Capital (ROIC)	-25.42%
Revenue Per Employee	n/a
Profits Per Employee	-$1.72M
Employee Count	254
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +54.77% in the last 52 weeks. The beta is 0.94, so Vaxcyte's price volatility has been similar to the market average.

Beta (1Y)	0.94
52-Week Price Change	+54.77%
50-Day Moving Average	65.85
200-Day Moving Average	59.04
Relative Strength Index (RSI)	72.34
Average Volume (30 Days)	705,954

Short Selling Information

The latest short interest is 8.43 million, so 7.75% of the outstanding shares have been sold short.

Short Interest	8.43M
Short Previous Month	8.24M
Short % of Shares Out	7.75%
Short % of Float	8.49%
Short Ratio (days to cover)	12.09

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-511.32M
Pretax Income	-436.82M
Net Income	-436.82M
EBITDA	-425.90M
EBIT	-436.82M
Earnings Per Share (EPS)	-$4.28

Full Income Statement

Balance Sheet

The company has $1.49 billion in cash and $27.42 million in debt, giving a net cash position of $1.46 billion or $13.41 per share.

Cash & Cash Equivalents	1.49B
Total Debt	27.42M
Net Cash	1.46B
Net Cash Per Share	$13.41
Equity / Book Value	1.98B
Book Value Per Share	18.24
Working Capital	1.43B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$408.22 million and capital expenditures -$74.34 million, giving a free cash flow of -$482.56 million.

Operating Cash Flow	-408.22M
Capital Expenditures	-74.34M
Free Cash Flow	-482.56M
FCF Per Share	-$4.32

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Vaxcyte does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-29.56%
Shareholder Yield	-29.56%
Earnings Yield	-5.41%
FCF Yield	-5.97%

Dividend Details

Analyst Forecast

The average price target for Vaxcyte is $96.00, which is 28.74% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$96.00
Price Target Difference	28.74%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-5.28%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2